{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:14:33Z","timestamp":1793150073847,"version":"4.5.0"},"reference-count":32,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,8,24]],"date-time":"2009-08-24T00:00:00Z","timestamp":1251072000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:p><jats:bold>Introduction:\u2002<\/jats:bold>Doxorubicin, an anthracycline widely used in the treatment of a broad range of tumours, causes acute QT prolongation. Dexrazoxane has been shown to prevent the QT prolongation induced by another anthracycline, epirubicin, but has not yet been reported to prevent that induced by doxorubicin. Thus, the present study was designed to test whether the acute QT effects induced by doxorubicin could be blocked by dexrazoxane and to explore the mechanism. Results were compared with those obtained with a reference human ether\u2010a\u2010go\u2010go (hERG) channel blocker, moxifloxacin.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold>The effects of moxifloxacin (100\u2003\u00b5M) and doxorubicin (30\u2003\u00b5M), with or without dexrazoxane (from 3 to 30\u2003\u00b5M), have been evaluated on the QTc interval in guinea\u2010pig isolated hearts and on<jats:italic>I<\/jats:italic><jats:sub>Kr<\/jats:sub>(rapid component of the delayed rectifier current) and<jats:italic>I<\/jats:italic><jats:sub>Ks<\/jats:sub>(slow component of the delayed rectifier current) currents stably expressed in human embryonic kidney 293 cells.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold>Moxifloxacin (100\u2003\u00b5M), a potent hERG blocker, prolonged QTc by 22%, and this effect was not prevented by dexrazoxane. Doxorubicin (30\u2003\u00b5M) also prolonged QTc by 13%, did not significantly block hERG channels and specifically inhibited<jats:italic>I<\/jats:italic><jats:sub>Ks<\/jats:sub>(IC<jats:sub>50<\/jats:sub>: 4.78\u2003\u00b5M). Dexrazoxane significantly reduced the doxorubicin\u2010induced QTc prolongation and prevented doxorubicin\u2010induced inhibition of<jats:italic>I<\/jats:italic><jats:sub>Ks<\/jats:sub>.<\/jats:p><jats:p><jats:bold>Conclusion and implications:\u2002<\/jats:bold>Doxorubicin acutely prolonged the QT interval in guinea\u2010pig heart by selective<jats:italic>I<\/jats:italic><jats:sub>Ks<\/jats:sub>blockade. This effect was prevented by dexrazoxane. This result is important because it illustrates the danger of neglecting<jats:italic>I<\/jats:italic><jats:sub>Ks<\/jats:sub>in favour of hERG screening alone, for early preclinical testing for possible induction of torsade de pointes.<\/jats:p><jats:p>This article is part of a themed section on QT safety. To view this issue visit<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www3.interscience.wiley.com\/journal\/121548564\/issueyear?year=2010\">http:\/\/www3.interscience.wiley.com\/journal\/121548564\/issueyear?year=2010<\/jats:ext-link><\/jats:p>","DOI":"10.1111\/j.1476-5381.2009.00371.x","type":"journal-article","created":{"date-parts":[[2009,8,24]],"date-time":"2009-08-24T10:01:54Z","timestamp":1251108114000},"page":"93-101","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Dexrazoxane protects the heart from acute doxorubicin\u2010induced QT prolongation: a key role for<i>I<\/i><sub>Ks<\/sub>"],"prefix":"10.1111","volume":"159","author":[{"given":"J","family":"Ducroq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Moha ou Maati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Guilbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Dilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Laemmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Pons\u2010Himbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JF","family":"Faivre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Bois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"St\u00fccker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Le Grand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,1,19]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80728-X"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706678"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/384078a0"},{"key":"e_1_2_8_5_1","first-page":"353","article-title":"An analysis of the time\u2010relations of electrocardiograms","volume":"7","author":"Bazett HC","year":"1920","journal-title":"Heart"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.24.6.322"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706389"},{"key":"e_1_2_8_8_1","first-page":"137","article-title":"Two components of delayed rectifier K+ current in heart: molecular basis, functional diversity, and contribution to repolarization","volume":"25","author":"Cheng JH","year":"2004","journal-title":"Acta Pharmacol Sin"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1H474"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.111482"},{"key":"e_1_2_8_11_1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.0954-6820.1920.tb18266.x","article-title":"Die Systolendauer im Elektrokardiogramm beinormalen Menschen and bei Herzkranken","volume":"57","author":"Fridericia LS","year":"1920","journal-title":"Acta Medica Scandinavica"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2004.12.003"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00656997"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.64.3.670"},{"key":"e_1_2_8_15_1","first-page":"4200","article-title":"Dose\u2010response relationship of dexrazoxane for prevention of doxorubicin\u2010induced cardiotoxicity in mice, rats, and dogs","volume":"56","author":"Imondi AR","year":"1996","journal-title":"Cancer Res"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.550111"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1542-474X.2007.00140.x"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.59.1.122"},{"key":"e_1_2_8_19_1","first-page":"53","article-title":"Sudden death in leukemic patient treated with doxorubicin","volume":"8","author":"Lacasse Y","year":"1992","journal-title":"Can J Cardiol"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.78.4.689"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2007.07.070"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-006-0609-0"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.1999.00480.x"},{"key":"e_1_2_8_24_1","first-page":"332","article-title":"Doxorubicin (Adriamycin) cardiomyopathy","volume":"139","author":"Saltiel E","year":"1983","journal-title":"West J Med"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/384080a0"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706721"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02994091"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19870915)60:6<1213::AID-CNCR2820600609>3.0.CO;2-V"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01096-2"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.76.4.645"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199856030-00009"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.101881"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000133187.74800.B9"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1476-5381.2009.00371.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1476-5381.2009.00371.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T01:23:45Z","timestamp":1710552225000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1476-5381.2009.00371.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1111\/j.1476-5381.2009.00371.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00371.x","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1]]},"assertion":[{"value":"2010-01-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}